Explain this page
Arphra AIPlain-English read on State Street SPDR S&P Pharmaceuticals ETF’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Candlestick · 1Y
Open in chart workstation →XPH
61.04+7.01%H 61.46L 51.26MA50 56.22MA200 —Avg vol 70K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.76% | +0.39% | +6.62% | +15.78% | +8.59% | +8.98% | +50.27% | +45.65% | +16.29% | +45.13% | +291.03% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$61.52
Bid
$57.29
100 sh
Ask
$66.99
100 sh
Spread
$9.700
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?zacks.com·Jun 05, 2026
- State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?fool.com·Jun 04, 2026
- Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?zacks.com·Jun 03, 2026
Peers
No peer list available for XPH.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|